Inhale and Baxter pause for breath in collaboration:
This article was originally published in Clinica
Inhale Therapeutic Systems and Baxter International are attempting to renegotiate their deal to develop Inhale's pulmonary drug delivery system. Just 18 months ago, Baxter announced that up to $80 million would be available to Inhale to cover development and trials, through milestone payments. At the time Baxter put in $20 million as equity investment. Inhale says that the scope of the agreement has increased and - as Inhale is in the middle of a public stock offering - it made the declaration that it is seeking a renegotiation.